GlassScriptPhysician profile
Radu Neamu
NPI 1083895577
$721.53
in general payments reported to CMS, 2019-2025
17 companies · $226 in 2025
The $226 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $245 · 2023: $103 · 2024: $148 · 2025: $226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $459 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $459.16 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $171.57 | 2019 | |
| Abiomed | $100.33 | 2024-2025 | Impella |
| Genzyme Corporation | $99.29 | 2019-2025 | |
| Inspire Medical Systems, INC. | $87.34 | 2023 | Inspire |
| Insmed, INC. | $58.62 | 2025 | Arikayce |
| Resmed Corp | $48.15 | 2025 | |
| Amgen INC. | $34.43 | 2025 | Tezspire |
| Grifols USA, LLC | $32.91 | 2024-2025 | Prolastin-C Liquid |
| Novartis Pharmaceuticals Corporation | $26.64 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $17.75 | 2024 | Breztri |
| United Therapeutics Corporation | $15.21 | 2023 | Tyvaso |
| Pfizer INC. | $14.97 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.32 | 2025 | Ofev |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Radu Neamu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.